Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-04-17 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业第八届董事会第二十九次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a specific board meeting of Jinling Pharmaceutical Co., Ltd. It details the convening of the 29th meeting of the 8th Board of Directors, the attendance, and the voting results on various proposals including the addition of a board committee member, amendments to company contract management, and approval of related-party transactions. The document does not contain financial statements or detailed financial analysis but focuses on board decisions and governance matters. It is not an annual report, earnings release, or regulatory filing of financial data. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2023-04-17 Chinese
金陵药业独立董事关于第八届董事会第二十九次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions related to a specific board meeting agenda item concerning the use of raised funds for loans to a subsidiary and related party guarantees. It references compliance with listing rules and company regulations but does not contain financial statements or detailed financial data. The document is short (596 characters) and serves as a formal opinion or approval rather than a report or announcement of voting results. It is related to board/management information as it concerns board meeting matters and independent directors' opinions on corporate governance issues. Therefore, the most appropriate classification is Board/Management Information (MANG).
2023-04-17 Chinese
金陵药业独立董事关于公司是否存在同业竞争及避免同业竞争有关措施有效性的独立意见
Governance Information Classification · 95% confidence The document is an independent opinion from the independent directors of Jinling Pharmaceutical Co., Ltd. regarding the existence of competition within the same industry and the effectiveness of measures to avoid such competition. It references company laws, securities laws, governance codes, and internal company rules. The content focuses on governance and compliance matters related to conflicts of interest and corporate control, rather than financial results, audit opinions, or shareholder meeting materials. It does not contain financial statements or earnings data, nor is it a call transcript or a report publication announcement. The document is a governance-related statement about board oversight and corporate governance practices, fitting the Governance Information (CGR) category.
2023-04-17 Chinese
金陵药业第八届监事会第二十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jinling Pharmaceutical Co., Ltd. It details the convening and voting results of a specific Supervisory Board meeting held on April 14, 2023, regarding the use of raised funds for loans to a subsidiary and related party guarantees. The document is short (806 characters) and serves as an official announcement of a board meeting decision rather than a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a regulatory certification or a report publication notice. It fits best under Board/Management Information (MANG) as it relates to internal governance decisions and board resolutions.
2023-04-17 Chinese
金陵药业股份有限公司关于召开2022年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of an online earnings explanation meeting (业绩说明会) related to the company's 2022 Annual Report, which was previously disclosed. It invites investors to participate and submit questions. The document does not contain the actual annual report or financial data but rather announces the event and provides details for investor engagement. The document length is short (809 characters), and it references a previously published annual report (公告编号：2023-031). According to the 'Menu vs Meal' rule, this is an announcement about a report-related event, not the report itself. Therefore, the appropriate classification is Investor Presentation (IP), as it is a detailed presentation event for investors focusing on financial results and company information.
2023-03-27 Chinese
金陵药业股份圾限公司关于特定股东减持股份计划时间过半暨减持进展情况的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the progress of a specific shareholder's share reduction plan, including details on the number of shares reduced, the reduction period, and compliance with relevant securities laws and regulations. It does not contain financial statements or detailed financial performance data. The content focuses on shareholding changes by a major shareholder and the regulatory compliance of the reduction plan. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2023-03-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.